New Diagnostic Tool for Minimal Hepatic Encephalopathy in Cirrhosis Patients

Breakthrough in Diagnosing Minimal Hepatic Encephalopathy

Researchers have developed a new diagnostic tool called Stroop-CN, which promises to revolutionize the detection of minimal hepatic encephalopathy (MHE) in patients with cirrhosis. This condition, often overlooked due to its subtle symptoms, can significantly impact a patient's quality of life and ability to perform daily tasks 1

1

Understanding Minimal Hepatic Encephalopathy

MHE is a neuropsychiatric complication that affects up to 80% of cirrhosis patients. It is characterized by mild cognitive impairment, attention deficits, and psychomotor slowing. Despite its prevalence, MHE often goes undiagnosed due to the lack of obvious clinical signs and the complexity of current diagnostic methods 2

2

The Stroop-CN Test: A Game-Changer in Diagnosis

The Stroop-CN test, developed by a team led by Dr. Jasmohan S Bajaj from Virginia Commonwealth University and McGuire VA Medical Center, is a modified version of the classic Stroop test. It incorporates culturally neutral stimuli, making it applicable across different populations. The test measures cognitive flexibility and inhibitory control, key areas affected by MHE 1

1

Advantages of Stroop-CN

1. Rapid administration: The test can be completed in under 5 minutes.
2. High accuracy: It demonstrated 81% sensitivity and 77% specificity in detecting MHE.
3. Cultural neutrality: The test uses shapes and colors instead of words, making it suitable for diverse populations.
4. Correlation with other measures: Stroop-CN results aligned well with established tests like EncephalApp and PHES 2

   2

   .

Related Stories

AI Algorithm Detects Undiagnosed Early-Stage Liver Disease, Promising Improved Patient Care

AI-Powered Portable System Detects Mild Cognitive Impairment with 83% Accuracy

AI-Enhanced EEG Analysis: A Breakthrough in Early Dementia Detection

EMA Approves AI Tool for MASH Clinical Trials: A Breakthrough in Liver Disease Research

Implications for Patient Care

Early detection of MHE is crucial for improving patient outcomes. The Stroop-CN test could enable healthcare providers to identify at-risk patients more efficiently, leading to timely interventions and better management of the condition. This, in turn, could enhance the quality of life for cirrhosis patients and potentially reduce the risk of overt hepatic encephalopathy 1

1

Future Prospects

The researchers suggest that the Stroop-CN test could be integrated into routine clinical practice, particularly in settings where more complex diagnostic tools are not available. Its simplicity and effectiveness make it a promising option for widespread adoption in the management of cirrhosis patients 2

2

As the medical community continues to validate and refine this new diagnostic tool, it holds the potential to significantly improve the care and outcomes for patients with cirrhosis and minimal hepatic encephalopathy.